Virus

Viriom's Single Pill Influenza Treatment Completes Critical Phase I Clinical Trials

Retrieved on: 
Monday, November 20, 2023
Safety, SAN, Nature, Virus, RNA, Vaccine

AV5124 is an extremely effective inhibitor of influenza virus RNA processing that is potent against all tested influenza types including viruses resistant to neuraminidase inhibitors (Tamiflu®) or cap-dependent endonuclease inhibitors (Zoflusa®).

Key Points: 
  • AV5124 is an extremely effective inhibitor of influenza virus RNA processing that is potent against all tested influenza types including viruses resistant to neuraminidase inhibitors (Tamiflu®) or cap-dependent endonuclease inhibitors (Zoflusa®).
  • The recently concluded Phase I clinical studies demonstrated remarkable safety and tolerability of AV5124.
  • The excellent safety profile and known potency of AV5124 against influenza virus supports advancing this compound into Phase II-III efficacy studies that will begin during this year's influenza season.
  • AV5124 is also a potent inhibitor of highly pathogenic avian influenza viruses circulating in nature, indicating the potential for seasonal or pandemic influenza treatment, and for pandemic preparedness.

Gene Splicing Reduces Effectiveness of CD20-Targeting Monoclonal Antibodies Designed to Treat Variety of Blood Cancers and Disorders

Retrieved on: 
Friday, November 17, 2023
DOI, DRS, Malignancy, CHOP, Research, University, Bone marrow, Leukemia, Blood, Hospital, Protein, Jim Valvano, Patient, Lymphoma, Division, Follicular lymphoma, Messenger, Child, Medical laboratory, Virus, Burkitt lymphoma, Antibody, Exon, Children's Hospital of Philadelphia, Doctor of Philosophy, Emerson Collective, MS4A1, Alternative splicing, Bangladesh Technical Education Board, Cell, RNA, Vaccine, Pathology, CD20

PHILADELPHIA, Nov. 17, 2023 /PRNewswire/ -- Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to these treatments due to a loss of the antigen that's being targeted. Now, a new study from researchers at Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania (Penn) has found that gene splicing occurring within these cells can cause significant changes in CD20 protein levels that render the therapies ineffective.

Key Points: 
  • PHILADELPHIA, Nov. 17, 2023 /PRNewswire/ -- Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated.
  • These findings may lead to more appropriate choices for therapy that maximize benefits to patients affected by a variety of blood cancers.
  • CD20 is a cell-surface protein involved in the fine-tuning of B cell responses to foreign agents like viruses.
  • Prior research had shown that a loss of CD20 reduced the effectiveness of these immunotherapies, since it would remove their intended target.

Cytonus expands its Scientific Advisory Board with Oncolytic Virus expert John C. Bell, PhD

Retrieved on: 
Thursday, November 16, 2023
Royal Society, ISCB Senior Scientist Award, Research, Therapy, Potyvirus, Ottawa Hospital Research Institute, Immunology, McGill University, Vaccine, Royal, Bell, Science, University, Cancer, Virus, Outline of health sciences, McMaster University, Doctor of Philosophy, Microbiology, Medical Research Council, University of Ottawa, Pharmaceutical industry, Management, Medicine, Biochemistry, MD

SAN DIEGO, Nov. 16, 2023 /PRNewswire-PRWeb/ -- Cytonus Therapeutics, Inc., announced today that the company has expanded its Scientific Board of Advisors with the appointment of University of Ottawa Professor and pioneering researcher in the field of oncolytic viruses John C. Bell, PhD.

Key Points: 
  • Board Expansion for Cytonus Therapeutics, Inc.
    SAN DIEGO, Nov. 16, 2023 /PRNewswire-PRWeb/ -- Cytonus Therapeutics, Inc., announced today that the company has expanded its Scientific Board of Advisors with the appointment of University of Ottawa Professor and pioneering researcher in the field of oncolytic viruses John C. Bell, PhD.
  • "It is a great privilege for Cytonus to be joined by Professor Bell, who is an international leader in the field of modern viral immunotherapeutics."
  • commented Cytonus' cofounder and Chief Scientific Innovator, Richard Klemke, PhD.
  • Cytonus' Scientific Advisory Board is comprised of accomplished business leaders, distinguished research scientists, and key opinion leaders from prestigious academic institutions, immune-oncology centers, cell therapy centers, and private industry.

ACROBiosystems launches GM-grade DLL4 Protein to accelerate stem cell manufacturing

Retrieved on: 
Thursday, November 16, 2023
Mycoplasma, IND, Uncertainty, Fibroblast, Growth, B cell, Risk, DLL4, Research, Safety, GMP, Virus, A-DNA, Quality assurance, Vaccine

The availability of DLL4 manufactured under GMP conditions represents a significant milestone for enterprises engaged in developing or manufacturing stem-cell based biologics.

Key Points: 
  • The availability of DLL4 manufactured under GMP conditions represents a significant milestone for enterprises engaged in developing or manufacturing stem-cell based biologics.
  • The GMP process guarantees that the DLL4 recombinant protein is consistent, contaminant-free, and developed in a controlled production environment for use as a raw material in stem cell culturing.
  • Conventionally, feeder cells such as OP9-DLL4 are employed to secrete DLL4 during the growth and differentiation of stem cells in vitro.
  • As such, these feeder cells are often utilized to stem cell research and develop potential therapies.

Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries

Retrieved on: 
Monday, November 13, 2023
World Health Organization, Pandemic, Tuberculosis, SAN, DNA, Organization, Disease, WHO, Risk, Genomics, Molecular epidemiology, Data analysis, Whole genome sequencing, Illumina, Inc., Drug resistance, Clinical epidemiology, SARS-COV-2, Virus, GISAID, AIDS, Communication, Moeder, SARS-CoV-2, Face, Public, Influenza-like illness, Vaccine, Renewable energy, Malaria, Developing country, Illumina

SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs). The program, developed with guidance from customers, funders, and market facilitators including the nonprofit FIND, will provide reduced pricing structures for eligible sequencing products from Illumina to qualified global health funding entities and address key international logistics and supply chain challenges.

Key Points: 
  • SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs).
  • "We know that enabling countries to perform pathogen sequencing locally strengthens health systems, enables better preparedness, and empowers countries to manage their priority health threats," said Vanessa Moeder, head of Global Health at Illumina.
  • In the Illumina global team's experience, Moeder says, the countries or regions whose public health preparedness would most benefit from genomics often lack the resources to sustainably implement it.
  • The equitable access program developed and operationalized by Illumina will allow many low- and middle-income nations to participate in the future of genomics across public health and preparedness."

Moleculin Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Webcast, Research, Safety, Clinical trial, STS, Patient, ANN, Conference, Cardiotoxicity, Private law, Virus, Metastasis, Virtual, R, AML, Pharmaceutical industry, Cryptocurrency

HOUSTON, Nov. 13, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today reported its financial results for the quarter ended September 30, 2023. As previously announced, the Company will host a conference call and live audio webcast, today, November 13, 2023, at 8:30 AM ET (details below).

Key Points: 
  • HOUSTON, Nov. 13, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today reported its financial results for the quarter ended September 30, 2023.
  • As previously announced, the Company will host a conference call and live audio webcast, today, November 13, 2023, at 8:30 AM ET (details below).
  • General and administrative expense was $2.6 million and $3.1 million for the three months ended September 30, 2023 and 2022, respectively.
  • Moleculin management will host its quarterly conference call and webcast for investors, analysts, and other interested parties today, November 13, 2023, at 8:30 AM ET.

Beyond2020 Improves Access to Clean Water for 10,000 Rural Malaysians

Retrieved on: 
Thursday, November 9, 2023
Ministry, Woman, Agriculture, Parasitism, Pressure, Climate change, Natural Resources, COP28, Rajang River, Heart, Drinking water, Health, Water resources, Bacteria, BNP Paribas, Diarrhea, Dysentery, Ultra, Virus, Water, Development, Partnership, Drinking, Electricity, Population growth, Environment, Renewable energy, Bottled water

Sustainable water fountains in 25 rural Malaysian communities provide clean, safe water, reducing waterborne illnesses

Key Points: 
  • Sustainable water fountains in 25 rural Malaysian communities provide clean, safe water, reducing waterborne illnesses
    ABU DHABI, UAE, Nov. 9, 2023 /PRNewswire/ -- Beyond2020, the UAE-driven humanitarian initiative, has installed water filters in 25 communities in the Sabah and Sarawak regions of Malaysia, providing clean drinking water to 10,000 people.
  • This deployment contributes significantly to Malaysia's ongoing efforts to enhance access to reliable, clean water.
  • The UAE's Beyond2020 initiative, which has delivered safe drinking water to 10,000 Malaysians, showcases how innovative solutions can tackle our water challenges, particularly in the rural areas.
  • Water interventions are necessary to ensure that vulnerable populations, particularly children, women and the elderly, have access to clean drinking water.

Beyond2020 Improves Access to Clean Water for 10,000 Rural Malaysians

Retrieved on: 
Thursday, November 9, 2023
Ministry, Woman, Agriculture, Parasitism, Pressure, Climate change, Natural Resources, COP28, Rajang River, Heart, Drinking water, Health, Water resources, Bacteria, BNP Paribas, Diarrhea, Dysentery, Ultra, Virus, Water, Development, Partnership, Drinking, Electricity, Population growth, Environment, Renewable energy, Bottled water

Sustainable water fountains in 25 rural Malaysian communities provide clean, safe water, reducing waterborne illnesses

Key Points: 
  • Sustainable water fountains in 25 rural Malaysian communities provide clean, safe water, reducing waterborne illnesses
    ABU DHABI, UAE, Nov. 9, 2023 /PRNewswire/ -- Beyond2020, the UAE-driven humanitarian initiative, has installed water filters in 25 communities in the Sabah and Sarawak regions of Malaysia, providing clean drinking water to 10,000 people.
  • This deployment contributes significantly to Malaysia's ongoing efforts to enhance access to reliable, clean water.
  • The UAE's Beyond2020 initiative, which has delivered safe drinking water to 10,000 Malaysians, showcases how innovative solutions can tackle our water challenges, particularly in the rural areas.
  • Water interventions are necessary to ensure that vulnerable populations, particularly children, women and the elderly, have access to clean drinking water.

EQS-News: cyan AG: Orange Slovakia extends its cybersecurity portfolio including cyan’s Child Protection and PC Protection

Retrieved on: 
Wednesday, December 13, 2023
Online, PC, Internet, Orange, Child protection, Crime, Corporation, Parent, Safety, Virus, Online shopping, Orange Slovensko

Munich, November 13, 2023 - cyan AG (XETR: CYR), a leading European and global provider of intelligent cybersecurity solutions and BSS/OSS platform services for communication service providers, today announced that Orange Slovensko, a member of Orange Group, has launched Child Protection and PC Protection products based on technology provided by cyan.

Key Points: 
  • Munich, November 13, 2023 - cyan AG (XETR: CYR), a leading European and global provider of intelligent cybersecurity solutions and BSS/OSS platform services for communication service providers, today announced that Orange Slovensko, a member of Orange Group, has launched Child Protection and PC Protection products based on technology provided by cyan.
  • By adding the solutions Online Ochrana PC (online PC protection) and Online Ochrana Deti (online child protection), we will be able to extend our protection service to some of the most vulnerable user-groups,” explained Alexandra Piskunova, Corporate and Brand Reputation of Orange Slovakia.
  • In multiple phases further features and solutions have been added, the latest being Child Protection and PC Protection.
  • Orange Slovakia has now successfully launched the whole integrated cybersecurity product range of cyan capable to protect Orange’s entire customer base.

New Testing Proves AURA Ion Bar™ Highly Effective in Combating COVID-19 and Other Airborne Pathogens

Retrieved on: 
Thursday, November 9, 2023
Hardware, Health, COVID-19, Artificial Intelligence, Infectious Diseases, Consumer Electronics, Health Technology, Technology, Streptococcus pneumoniae, Viral pneumonia, AURA, Thought, SARS-CoV-2, Ion, Atmosphere, Virus, COVID, Naïs, Bacteria, Aspergillus fumigatus, Safety, Vaccine, Environmental remediation, Pharmaceutical industry

In a market flooded with safety products lacking adequate testing, AURA was determined to guarantee that the Ion Bar™ performed as advertised.

Key Points: 
  • In a market flooded with safety products lacking adequate testing, AURA was determined to guarantee that the Ion Bar™ performed as advertised.
  • Surface testing involved inoculating glass slides with SARS-CoV-2, while aerosol testing saw the virus nebulized and sprayed into the chamber to simulate airborne transmission.
  • Streptococcus Pneumoniae: This in-vitro study consisted of aerosol and surface testing to determine the efficacy of the AURA Ion Bar™ Mark IV against Streptococcus Pneumoniae.
  • To learn more about the AURA Ion Bar™ and its capabilities, please visit here .